The latest price target for Cyclo Therapeutics (NASDAQ:CYTH) was reported by Maxim Group on August 27, 2024. The analyst firm set a price target for $0.00 expecting CYTH to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Cyclo Therapeutics (NASDAQ:CYTH) was provided by Maxim Group, and Cyclo Therapeutics downgraded their hold rating.

The last upgrade for Cyclo Therapeutics Inc happened on September 27, 2023 when Maxim Group raised their price target to $4. Maxim Group previously had a hold for Cyclo Therapeutics Inc.

The last downgrade for Cyclo Therapeutics Inc happened on August 27, 2024 when Maxim Group changed their price target from N/A to N/A for Cyclo Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cyclo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cyclo Therapeutics was filed on August 27, 2024 so you should expect the next rating to be made available sometime around August 27, 2025.

While ratings are subjective and will change, the latest Cyclo Therapeutics (CYTH) rating was a downgraded with a price target of $0.00 to $0.00. The current price Cyclo Therapeutics (CYTH) is trading at is $0.71, which is out of the analyst’s predicted range.